Novartis AG filed a new lawsuit seeking to block Apotex Inc.’s proposed generics of its lucrative cancer drug Mekinist for more than seven years, alleging the copies and their intended uses infringe six patents.
Apotex’s generic 1-milligram tablets of trametinib, Mekinist’s active ingredient, infringe US Patent Nos. 8,580,304, 9,155,706, 9,271,941, and 9,399,021, which cover the tablets’ formulations, Novartis told the US District Court for the District of Delaware Monday.
The complaint also alleged infringement of US Patent Nos. 8,703,781 and 10,869,869 when Apotex’s Mekinist copies are used with generic dabrafenib, the active ingredient in Novartis’ Tafinlar, …